title: Gefitinib-induced paronychia: response to autologous platelet-rich plasma.
abstract: BACKGROUND
  Paronychia has been reported in as many as 10% of patients treated with gefitinib. Although conservative management and treatment with topical or systemic antibiotics are beneficial, no effective method exists for intractable cases. Platelet-rich plasma (PRP)consists of a high concentration of platelets that promote wound healing through chemotaxis, cell proliferation,angiogenesis, and tissue remodeling.
  
  
  METHODS
  We herein report a refractory case of gefitinib-induced paronychia successfully treated with autologous PRP. A 68-year-old woman who had been diagnosed as having lung adenocarcinoma with multiple bone and brain metastases initiated gefitinib therapy at an oral dose of 250 mg/d. After 1 month, multiple paronychia with periungual granulation appeared on the nailfold of the first, second, and third toenails of both feet.Because the paronychia recurred repeatedly despite use of a topical antibiotic, topical corticosteroid, and short term systemic antibiotic, she started PRP treatment. After 3 months, the lesion showed marked improvement with minimal pain or discharge.
  
  
  CONCLUSIONS
  This case highlights the therapeutic challenges of using PRP to promote tissue repair in intractable gefitinib-induced paronychia and merits further investigation.
authors.forename: Soon-Hyo
authors.initials: SH
authors.lastname: Kwon
authors.forename: Jae-Woo
authors.initials: JW
authors.lastname: Choi
authors.forename: Jong-Soo
authors.initials: JS
authors.lastname: Hong
authors.forename: Sang-Young
authors.initials: SY
authors.lastname: Byun
authors.forename: Kyoung-Chan
authors.initials: KC
authors.lastname: Park
authors.forename: Sang-Woong
authors.initials: SW
authors.lastname: Youn
authors.forename: Chang-Hun
authors.initials: CH
authors.lastname: Huh
authors.forename: Jung-Im
authors.initials: JI
authors.lastname: Na
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D010304:Paronychia / Q000139:chemically induced* / Q000628:therapy; D053657:Platelet-Rich Plasma; D011799:Quinazolines / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib